Breaking News, Collaborations & Alliances

Kymab, Roche Partner to Evaluate KY1044

Roche to provide PD-L1 blocking antibody atezolizumab in combination in Kymab’s upcoming Phase I-II clinical studies

Kymab Group Ltd has entered a clinical trial agreement with Roche. Under the agreement, Roche will provide its PD-L1 blocking antibody atezolizumab for use in combination in Kymab’s upcoming Phase I-II clinical studies combining its lead investigational anti-ICOS antibody therapy KY1044 in patients with advanced solid cancers. Kymab will be responsible for conducting the clinical trials, and both companies will share data from the trials. Kymab continues to retain all commercial rights to KY1044...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters